Table 2 Anthropometric and hormonal profile of patients at diagnosis and after 3 and 6 months on cabergolin treatment
From: Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
Parameter | Baseline | Cabergoline treatment | P value | ||
|---|---|---|---|---|---|
3 months | 6 months | * | † | ||
Body weight (kg)a | 57.3 (9.5) | 56.6 (9.1) | 54.8 (9.2) | .029 | <.001 |
BMI (kg/m2)a | 24.2 (4.0) | 23.9 (4.2) | 23.2 (3.9) | .09 | <.001 |
Waist (cm)a | 85.3 (12.0) | 84.9 (11.3) | 82.3 (10.0) | .30 | .003 |
Waist-hip ratioa | 0.9 (0.06) | 0.9 (0.06) | 0.9 (0.07) | .89 | .039 |
Body fat (kg) | 23.4. (10.4) | – | 22.3 (11.8) | – | <.001 |
PRL (µg/L) | 118.6 (105.3) | 10.45 (20.0) | 9.4 (5.9) | <.001 | <.001 |
TSH (U/L)a | 3.4 (1.7) | 3.7 (2.0) | 4.3 (1.3) | .60 | .09 |
T4 (nmol/l)a | 110.5 (25.2) | 125.3 (33.9) | 114.4 (22) | .10 | .60 |
Fasting glucose (mmol/l)a | 4.8 (0.5) | 4.6 (0.4) | 4.3 (0.3) | .006 | <.001 |
Fasting insulin (pmol/L) | 34.3 (54.6) | 37.6 (43.3) | 32.2 (20.9) | .62 | .24 |
HOMA-IR | 1.1 0 (1.27) | 1.21 (1.10) | 1.04 (0.52) | .71 | .064 |
Total cholesterol (mmol/l)a | 4.5 (1.0) | 4.1 (0.8) | 3.6 (0.5) | .11 | .009 |
LDL-cholesterol (mmol/l) | 2.8 (0.9) | 2.3 (0.5) | 2.0 (0.3) | .01 | <.001 |
HDL-cholesterol (mmol/l) | 1.1 (0.3) | 1.0 (0.2) | 1.1 (0.2) | .36 | .32 |
Triglycerides (mmol/l)a | 1.8 (0.4) | 1.3 (0.4) | 1.2 (0.2) | .004 | <.001 |
FSH (IU/l) | 6.0 (3.8) | 5.6 (4.0) | 5.6 (3.2) | .87 | 1.00 |
LH (IU/l) | 5.1 (7.4) | 5.23 (2.7) | 5.3 (1.3) | .62 | .54 |
Estradiol (pg/ml)a | 52.7 (24.3) | 87.7 (54.5) | 63.4 (167.4) | .004 | .12 |